

Disclosure Results

Jardiance

European Marketing Authorisation Holder: Boehringer Ingelheim International GmbH

| phase | total complete by 31 July 2016 | un-evaluable | evaluable | disclosed in 12 month timeframe | disclosed percentage at 12 months | complete by 31 July 2016 | disclosed at 31 July 2016 | disclosure percentage at 31st July 2016 |
|--------------|--------------------------------------|--------------|-----------|---------------------------------------|---|-----------------------------|------------------------------|--|
| phase I & II | 18 | 2 | 16 | 16 | 100% | 16 | 16 | 100% |
| phase III | 15 | 0 | 15 | 15 | 100% | 15 | 15 | 100% |
| phase IV | 1 | 1 | 0 | 0 | | 0 | 0 | |
| other | 0 | 0 | 0 | 0 | | 0 | 0 | |
| total | 34 | 3 | 31 | 31 | 100% | 31 | 31 | 100% |

Key to columns in table above:

total complete by 31 July 2016 = total number of company-sponsored trials identified which were completed by 31 July 2016

unevaluable = trials with completion date within the last 12 months, or key dates missing - excluded from the analysis

evaluable = trials with all criteria present including dates; hence the base number of trials evaluated for the assessment

disclosed in 12 month timeframe = evaluable trials which were disclosed within the target 12 months*

disclosed percentage at 12 months = proportion of evaluable trials which were disclosed within 12 months*

complete before 31 July 2016 = number of evaluable trials completed before 31 July 2016

disclosed at 31 July 2016 = number of evaluable trials with results disclosed by 31 July 2016

disclosure percentage at 31 July 2016 = proportion of evaluable trials which were disclosed by 31 July 2016

[* 12 months measured from the later of: the first date of regulatory approval (in Europe or the US) or the trial completion date]